Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Sep;18(9):1492-6.
doi: 10.1128/CVI.05020-11. Epub 2011 Jul 13.

Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers

Affiliations
Clinical Trial

Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers

Helen Findlow et al. Clin Vaccine Immunol. 2011 Sep.

Abstract

A phase II clinical study was conducted in African toddlers (aged 12 to 23 months), with subjects receiving either investigational meningococcal group A conjugate (PsA-TT), meningococcal ACWY polysaccharide (PsACWY), or Haemophilus influenzae type b (Hib-TT) vaccine. Ten months following vaccination, the 3 study groups were further randomized to receive a dose of PsA-TT, a 1/5 dose of PsACWY, or a dose of Hib-TT vaccine. Group A serum bactericidal antibody (SBA) results have been reported previously, with PsA-TT demonstrating superior immunogenicity versus PsACWY vaccine. Immunogenicity for serogroups W135 and C was assessed by SBA assay to investigate the impact of multiple doses in this age group. Blood samples were taken prior to vaccination, 28 days and 40 weeks post-primary vaccination, and 7 and 28 days post-booster vaccination with a 1/5 dose of PsACWY. Subjects who had previously received a full dose of PsACWY had W135 SBA geometric mean titers (GMTs) of 26.1 and 4.4 at 7 and 28 days post-booster vaccination with a 1/5 PsACWY dose, respectively, whereas the W135 SBA GMTs of naïve subjects at these time points following vaccination with a 1/5 dose of PsACWY were 861.1 and 14.6, respectively. Similar differences were observed for serogroup C, with SBA GMTs of 99 and 5.9 at 7 and 28 days post-booster vaccination with a 1/5 dose of PsACWY, respectively, for naïve subjects, compared to 4.1 and 3.2 for previously vaccinated subjects. Immunologic hyporesponsiveness for groups C and W135 was observed following a full dose of PsACWY vaccine at 12 to 23 months of age and a 1/5 dose of PsACWY 10 months later compared to the case for PsACWY-naïve subjects receiving a 1/5 dose of PsACWY vaccine.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Serogroup C and W135 SBA GMTs for the four groups prior to vaccination, 28 days and 10 months post-primary vaccination, and 7 and 28 days post-booster vaccination.

References

    1. Al-Mazrou Y. Y., et al. 2005. Immunogenicity of a meningococcal ACYW135 polysaccharide vaccine in Saudi children aged under 5 years. Infect. Immun. 73:2932–2939 - PMC - PubMed
    1. Andrews N., Borrow R., Miller E. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10:780–786 - PMC - PubMed
    1. Borrow R. 2009. Meningococcal disease and prevention at the Hajj. Travel Med. Infect. Dis. 7:219–225 - PubMed
    1. Gold R., Lepow M. L., Goldschneider I., Draper T. L., Gotschlich E. C. 1975. Clinical evaluation of group A and group C meningococcal polysaccharide vaccine in infants. J. Clin. Invest. 56:1536–1547 - PMC - PubMed
    1. Jokhdar H., et al. 2004. Immunologic hyporesponsiveness to group C but not group A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin. Diagn. Lab. Immunol. 11:83–88 - PMC - PubMed

Publication types

MeSH terms